STOCK TITAN
  1. Home
  2. News
  3. RLYB

Rallybio Corporation - $RLYB STOCK NEWS

Welcome to our dedicated page for Rallybio Corporation news (Ticker: $RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rallybio Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rallybio Corporation's position in the market.

News
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
Rhea-AI Summary

Rallybio (Nasdaq: RLYB) will present at the 2024 Citizens JMP Life Sciences Conference. Steve Uden, M.D., CEO, will participate in a fireside chat on May 14, 2024, at 11:30 a.m. ET in New York. The event will be live webcasted on Rallybio's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
News
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
Rhea-AI Summary
Rallybio (Nasdaq: RLYB) presented findings from a systematic literature review and meta-analysis on fetal and neonatal alloimmune thrombocytopenia (FNAIT) at the Academy of Managed Care Pharmacy 2024 Annual Meeting. The research revealed that 2.2% of 198,062 pregnant women were HPA-1a negative, with 32.3% of them at a higher risk for alloimmunization. Rallybio is developing RLYB212, a monoclonal antibody to prevent FNAIT, with plans for a Phase 2 study in pregnant women in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
none
-
News
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Rhea-AI Summary
Rallybio partners with Johnson & Johnson to develop therapies for FNAIT, receives $6.6 million investment. RLYB212 aims to prevent FNAIT in pregnant individuals. Phase 2 study planned for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
82.82%
Tags
none
News
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
Rhea-AI Summary
Rallybio (RLYB) to present data on Fetal and Neonatal Alloimmune Thrombocytopenia at AMCP 2024 Annual Meeting. The company is developing RLYB212 to prevent FNAIT in pregnant mothers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
none
-
News
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Rallybio Corporation (RLYB) receives Protocol Assistance Feedback from European Medicines Agency on Phase 2 Study for RLYB212, plans to proceed with Clinical Trial Application Process in Europe. Phase 2 Dose Confirmation Study for RLYB212 in Pregnant Women at Higher Risk for FNAIT set to start in 2H 2024. The company has $109.9 million in Cash, Cash Equivalents, and Marketable Securities as of December 31, 2023, providing financial runway into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.7%
Tags
earnings
-
News
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) announced that its CEO will participate in a panel discussion on Orphan Bone & Neuromuscular Diseases at the TD Cowen 44th Annual Health Care Conference. The live webcast can be accessed on Rallybio's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
conferences
News
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) announces the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116. The company expects to extend its cash runway into mid-2026. RLYB212 is a monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia, while RLYB116 is a C5 inhibitor for patients with complement-mediated diseases. The workforce reduction will result in approximately $3.3 million in charges, but the company's cash, cash equivalents, and marketable securities of $109.9 million as of December 31, 2023, are expected to fund its operating plan into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24%
Tags
none
-
News
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) provides updates on recent accomplishments and expected 2024 milestones, including the initiation of a Phase 2 study for RLYB212, discussions with the European Medicines Agency, and extended cash runway into 3Q 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
-
News
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, showing a mean reduction of greater than 93% in free C5 with low volume once-a-week subcutaneous dosing. The data supports the study of RLYB116 as a differentiated therapeutic for the treatment of Generalized Myasthenia Gravis. The company also announced an extension of runway to 3Q 2025 as part of portfolio prioritization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
clinical trial
News
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) presented details from the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study at the 65th American Society of Hematology (ASH) Annual Meeting. The study aims to determine the frequency of expectant mothers of diverse races and ethnicities at higher FNAIT risk, with a prospective goal of screening up to 30,000 expectant mothers and an estimated 7,600 women screened by the end of 2023. The study is designed to provide a contemporary control dataset to support a future registrational trial in pregnant women.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock RLYB logo
Rallybio Corporation

Nasdaq:RLYB

RLYB Rankings

#4491 Ranked by Market Cap
#4864 Ranked by Stock Gains
N/A Ranked by Dividends

RLYB Stock Data

76.68M
20.76M
5.62%
87.18%
3.47%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
NEW HAVEN

About RLYB

rallybio is a privately-held early-stage biotechnology company incorporated in january 2018. our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. we will work on highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. rallybio’s founders are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. the company is based in farmington, ct, at the university of connecticut’s technology incubation program. we are assembling a small team of people with an outstanding track record in pharmaceutical research and development to search for and evaluate assets using a series of robust clinical and commercial filters tha